Developer of gene delivery hardware designed to unlock gene-modified cell therapy for the masses. The company's hardware is based on microfluidic technology that uses microfluidic vortex shedding to enable fast processing of small and large volumes of human primary immune cells and it can achieve high yield with a simple workflow and does not change human primary immune cell activation or exhaustion profiles, enabling efficient development and scalable manufacturing of gene-modified cell therapies.
Generating Revenue/Not Profitable
Privately Held (backing)
Venture Capital-Backed